ABRAXIS PHARM
PharmaABRAXIS PHARM is a pharmaceutical company focused on Dermatology, Oncology, Cardiovascular.
ABRAXIS PHARM's Key Drugs
ABRAXIS PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ABRAXIS PHARM's Recent FDA Approvals
New NDA/BLA approvals for ABRAXIS PHARM over the last two years — novel drugs only, excluding generics and label supplements.
ABRAXIS PHARM's Therapeutic Areas
ABRAXIS PHARM's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ABRAXIS PHARM's Top Competitors
ABRAXIS PHARM's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ABRAXIS PHARM Pipeline Snapshot
Active clinical trials for ABRAXIS PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1972-02-15
- Latest
- 2003-01-06
- Applications
- 113